SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (3149)6/2/1999 11:23:00 AM
From: quidditch  Read Replies (2) | Respond to of 10280
 
Don, Peter:

I wonder if ongoing discussions with the FTC with respect to the LLY-prozac issue had anything to do with the structuring of this particular license with UBC. One could infer both postives and negatives from a possible linkage. And I don't mean to imply that I think that the FTC has much of a case regarding LLY.

Any comments?

Regards. Steven



To: Don Miller who wrote (3149)6/2/1999 12:06:00 PM
From: dalroi  Read Replies (1) | Respond to of 10280
 
DON
Its UCB and not UBC

i omited rest of the world as us and japan are the most important countries for revenue

this is an antiallergic drug so its used for comfort
i think that the majority of the rest of teh world has no money to pay for this "luxus"

as far as belgium is concerned UCB markets zyrtec alone


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News